Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pazopanib
Drug ID BADD_D01687
Description Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Indications and Usage Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
Marketing Status approved
ATC Code L01EX03
DrugBank ID DB06589
KEGG ID D05380
MeSH ID C516667
PubChem ID 10113978
TTD Drug ID Not Available
NDC Product Code Not Available
UNII 7RN5DR86CK
Synonyms pazopanib | GW 786034B | GW786034B | GW-786034B | GW 780604 | GW780604 | GW-780604 | Votrient
Chemical Information
Molecular Formula C21H23N7O2S
CAS Registry Number 444731-52-6
SMILES CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bone marrow failure01.03.03.0050.001007%
Nephritic syndrome20.05.01.0060.000112%-
Bronchial haemorrhage22.03.02.007; 24.07.01.045---
Treatment failure08.06.01.017---
Liver injury09.01.07.022; 12.01.17.0120.000504%-
Regurgitation07.01.07.0040.000246%-
Oral disorder07.05.01.0050.000381%-
Renal cell carcinoma16.08.02.002; 20.01.04.0030.004667%-
Hypertransaminasaemia09.01.02.0050.000392%-
Oropharyngeal pain07.05.05.004; 22.12.03.016--
Gastrointestinal tract irritation07.08.03.0080.000381%-
Posterior reversible encephalopathy syndrome17.13.02.0070.001063%
Drug-induced liver injury09.01.07.023; 12.03.01.0440.000783%-
Autoimmune haemolytic anaemia01.06.01.004; 10.04.01.0050.000168%-
Faeces soft07.01.03.0080.000437%-
Multiple organ dysfunction syndrome08.01.03.0570.001343%
Anal incontinence07.01.06.029; 17.05.01.0210.000571%
Frustration tolerance decreased19.04.02.0160.000246%-
Ureterolithiasis20.04.03.0030.000112%-
Angiosarcoma16.16.03.001; 24.03.06.0030.000560%-
Bone cancer15.09.03.012; 16.29.02.0020.000168%-
Brain neoplasm malignant16.30.04.002; 17.20.04.0020.000302%-
Concomitant disease aggravated08.01.03.0630.000750%-
Dermatitis exfoliative generalised10.01.01.029; 23.03.07.0020.000224%-
Ewing's sarcoma15.09.03.015; 16.29.03.0040.000112%-
Faeces pale07.01.03.0050.000548%-
Leiomyosarcoma15.09.03.016; 16.33.07.0010.000168%-
Leiomyosarcoma metastatic15.09.03.017; 16.33.07.0020.000112%-
Liposarcoma15.09.03.005; 16.33.05.0010.000112%-
Malignant pleural effusion16.32.03.014; 22.05.04.0010.000224%-
The 18th Page    First    Pre   18 19 20 21    Next   Last    Total 21 Pages